Tokyo and Basking Ridge, NJ – (October 30, 2024) – The first patients have been dosed in three global, randomized phase 3 trials...

MONDAY, Oct. 21, 2024 -- ⁸⁹Zr-labeled monoclonal antibody ([⁸⁹Zr]Zr-girentuximab) for positron emission tomography-computed tomography...

MONDAY, Oct. 21, 2024 -- Pembrolizumab plus chemotherapy improves disease-free survival (DFS) in patients with high-risk endometrial cancer after...

In a new study led by Johns Hopkins Medicine, the drug RK-33 has demonstrated promise in treating breast cancer that has spread to the bone (breast...

Pre-surgery treatment with the novel drug vidutolimod and the PD-1 checkpoint inhibitor nivolumab led to tumor control in 55% of patients with stage 3...

A drug used in cancer treatment has the potential to save the limbs of thousands of cardiac patients with blocked arteries, a study has found.

A new drug called WNTinib can delay the growth of tumors and improve survival in hepatoblastoma, a type of liver cancer that occurs in young children.

BriaCell Therapeutics (TSX:BCT) reveals new positive survival data in its Phase 2 metastatic breast cancer study.

Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a 'magic bullet' strategy that combines the precision...

Intellia presents positive results from the Phase 2 Study of NTLA-2002, an investigational in vivo crispr gene editing treatment for hereditary...